SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 14.81 |
| Enterprise Value ($M) | 25.16 |
| Book Value ($M) | 9.20 |
| Book Value / Share | 1.07 |
| Price / Book | 1.61 |
| NCAV ($M) | -5.13 |
| NCAV / Share | -0.60 |
| Price / NCAV | -2.89 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -1.03 |
| Return on Assets (ROA) | -0.61 |
| Return on Equity (ROE) | -1.57 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 0.91 |
| Current Ratio | 0.91 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 19.70 |
| Assets | 34.02 |
| Liabilities | 24.82 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Earnings Per Share Basic And Diluted | n/a |
| Earnings Per Share Diluted | n/a |
| Earnings Per Share Basic | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Opaleye Management Inc. | 7.63 | 0.00 | |
| 13G | ADAR1 Partners, LP | 9.27 | ||
| 13G | Lynx1 Capital Management LP | 9.99 | ||
| 13G/A | Vanguard Group Inc | 0.23 | ||
| 13G | Sabby Management, Llc | 9.99 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A AMENDMENT NO. 1 | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 7,412 | 60,203 | 12.31 | |
| 70,613 | 250,564 | 28.18 | |
| 14,717 | 99,189 | 14.84 | |
| 63,819 | 167,580 | 38.08 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| CPHI – China Pharma Holdings, Inc. | CVM – CEL-SCI Corporation |
| CYBN – Cybin Inc. | IGC – IGC Pharma, Inc. |
| LCTX – Lineage Cell Therapeutics, Inc. |
Financial data and stock pages provided by
Fintel.io